Point72 Asset Management L.P. Invests $11.90 Million in Immunocore Holdings plc (NASDAQ:IMCR)

Point72 Asset Management L.P. bought a new position in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 403,304 shares of the company's stock, valued at approximately $11,897,000. Point72 Asset Management L.P. owned 0.81% of Immunocore as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently modified their holdings of the company. Jefferies Financial Group Inc. bought a new position in shares of Immunocore during the fourth quarter worth about $4,868,000. Hudson Bay Capital Management LP grew its position in shares of Immunocore by 31.5% during the fourth quarter. Hudson Bay Capital Management LP now owns 325,300 shares of the company's stock worth $9,596,000 after acquiring an additional 78,000 shares during the last quarter. Deep Track Capital LP bought a new position in shares of Immunocore during the fourth quarter worth about $15,322,000. Crestline Management LP bought a new position in shares of Immunocore during the fourth quarter worth about $736,000. Finally, Cubist Systematic Strategies LLC bought a new position in Immunocore in the 4th quarter valued at about $3,145,000. 84.50% of the stock is owned by institutional investors and hedge funds.

Immunocore Price Performance

NASDAQ IMCR traded down $0.05 on Friday, reaching $31.16. The company's stock had a trading volume of 98,828 shares, compared to its average volume of 388,676. Immunocore Holdings plc has a twelve month low of $23.15 and a twelve month high of $49.05. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. The stock has a market cap of $1.56 billion, a PE ratio of -32.80 and a beta of 0.75. The firm's 50 day moving average is $29.01 and its two-hundred day moving average is $30.01.

Immunocore (NASDAQ:IMCR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $0.10 earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.45. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The company had revenue of $125.13 million during the quarter, compared to the consensus estimate of $108.82 million. During the same period in the prior year, the company earned ($0.49) EPS. Immunocore's revenue was up 33.6% on a year-over-year basis. As a group, sell-side analysts predict that Immunocore Holdings plc will post -0.94 EPS for the current year.

Insider Buying and Selling at Immunocore

In other news, Director Bros. Advisors Lp Baker acquired 807,338 shares of Immunocore stock in a transaction on Monday, March 17th. The stock was bought at an average cost of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the purchase, the director now owns 2,144,060 shares of the company's stock, valued at $63,721,463.20. This represents a 60.40% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 10.40% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on IMCR shares. HC Wainwright reiterated a "buy" rating and issued a $100.00 target price on shares of Immunocore in a research report on Wednesday, March 12th. Mizuho decreased their target price on shares of Immunocore from $38.00 to $33.00 and set a "neutral" rating for the company in a research report on Monday, April 7th. Needham & Company LLC reiterated a "buy" rating and issued a $71.00 target price on shares of Immunocore in a research report on Thursday, April 10th. JPMorgan Chase & Co. decreased their target price on shares of Immunocore from $54.00 to $50.00 and set an "overweight" rating for the company in a research report on Monday, April 14th. Finally, Oppenheimer increased their target price on shares of Immunocore from $85.00 to $86.00 and gave the company an "outperform" rating in a research report on Thursday, May 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $58.13.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.